Latest News about treatment/resistant depression
Recent news which mentions treatment/resistant depression
Atai's DMT Depression Drug Shows Promise, Prepares For Phase II Trial And Future Collaboration With Pharma Giant
August 14, 2024
Tickers
ATAI
From Benzinga
Pharma Giant Johnson & Johnson Asks FDA To Approve Esketamine Nasal Spray For Treatment-Resistant Depression
July 23, 2024
From Benzinga
From Benzinga
Compass Pathways Shows Robust 2023 Year-End Results, Embraces Clinical Milestones For Psilocybin As Depression Treatment
February 29, 2024
Tickers
CMPS
From Benzinga
From Benzinga
Compass Pathways Explores AI-Powered Predictive Model On Psilocybin Therapy For Depression
September 06, 2023
Tickers
CMPS
From Benzinga
GH Research Psychedelics Firm Q2 2023 Reports $238M Cash To Accelerate 5-MeO-DMT Programs Into 2026
August 24, 2023
Tickers
GHRS
From Benzinga
Compatibility Of Psilocybin & SSRIs For Depression, COMPASS Looks At 'Psychedelic-Assisted Therapies'
July 18, 2023
Tickers
CMPS
From Benzinga
From Benzinga
From Benzinga
GH Research: Q1 2023 Financials And Businesses For European 5-MeO-DMT Depression Treatment Developer
May 11, 2023
Tickers
GHRS
From Benzinga
From Benzinga
Cathie Wood Reacts To Atai's Drastic Stock Plunge After Doomed Clinical Study Results
January 12, 2023
From Benzinga
Magic Mushrooms Tested For Treating Type II Bipolar Disorder, Check Out Results So Far
December 12, 2022
Tickers
CMPS
From Benzinga
Psychedelics And Treatment-Resistant Depression: COMPASS Pathways Replies To Comments
December 09, 2022
Tickers
CMPS
From Benzinga
Psychedelics And Treatment-Resistant Depression: An Overview Of COMPASS' Latest Trial Outcomes
November 16, 2022
Tickers
CMPS
From Benzinga
Psychedelics Company's $60M Series A For Startup To Develop Treatment For Mental Health Disorders
November 02, 2022
From Benzinga
Psilocybin For Anorexia: Learn About Compass' Novel Phase 2 Trial Using Magic Mushroom's Main Compound
July 28, 2022
Tickers
CMPS
From Benzinga
Psilocybin More Effective Than Antidepressants In Treating Depression, New Study Shows
April 12, 2022
From Benzinga
COMPASS Pathways: Positive Psilocybin Trial, High-Dose Group Improves Beyond Depression Reduction
December 01, 2021
Tickers
CMPS
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.